Qbrexza vs Botox for underarm sweating: compare two different trial outcomes

Qbrexza and BOTOX are FDA approved for different labeled underarm sweating populations. Qbrexza is a prescription glycopyrronium cloth for primary axillary hyperhidrosis in patients age 9 and older. BOTOX is approved for severe primary axillary hyperhidrosis inadequately managed with topical agents; its label says safety and effectiveness for this use have not been established under age 18. Their separate trials do not establish which works better head-to-head.¹²³

Compare the decision each prescription serves

A clinician can assess whether sweating is primarily underarm sweating or whether a new or more widespread pattern needs a different evaluation. The choice between a topical prescription and a procedure then has practical consequences: what the clinician reviews beforehand, who follows changes and which adverse effects are relevant. The BOTOX underarm indication does not answer a question about scalp or hand sweating. The Qbrexza label likewise describes primary axillary disease.¹²

Do not put unlike response numbers in the same ranking

In the two ATMOS studies summarized in the Qbrexza label, a diary-based response at week four was reported in 53% versus 28% and 66% versus 27%, respectively, for the cloth versus its vehicle. The trials also measured sweat output separately. Those are two outcomes even though they concern the same problem.¹

The separate published BMJ BOTOX study in adults reported that 227 of 242 toxin recipients and 28 of 78 placebo recipients reached its endpoint of at least 50% measured sweat reduction at week four. That response was defined by measured sweat output, not the Qbrexza diary scale. The populations, response definitions and comparators differed. A higher response number from one study does not establish superiority over the other treatment.¹³

Choose an outcome you can explain without a study scale

A person who wants to know whether sweating interferes less with work may care more about daily experience than about the quantity collected during a visit. Someone comparing two treatment plans can still ask each clinician what its trial measured and whether the proposed follow-up uses the same measure. The answers may legitimately differ. A clinic cannot convert one trial’s diary score to the other trial’s sweat-output response just by expressing both as percentages. Before comparing costs or convenience, identify what success would look like and who would check it.¹²³

Keep the safety discussions product-specific

The Qbrexza label discusses anticholinergic effects, including temporary blurred vision, urinary retention and problems related to reduced sweating in heat. Contact your clinician right away if you develop new or worsening trouble urinating, frequent urination, a weak stream or dribbling, a feeling of a full bladder, or difficulty emptying it.¹

The label also calls for contacting your clinician right away for signs of heat illness, such as hot, red skin or fever in hot conditions. Get emergency care if you become less alert, lose consciousness, have a fast, weak pulse or develop fast, shallow breathing in the heat.¹⁴

BOTOX has different warnings. Seek immediate medical attention for difficulty swallowing, speaking or breathing after a botulinum toxin injection. The prescribing information lists these as urgent symptoms rather than part of judging how much the underarms sweat.²

If you use the neuromodulator directory to find an office, ask whether it evaluates primary underarm hyperhidrosis and can discuss topical alternatives or coordinate with the prescriber. The miraDry comparison addresses a separate device decision. Neither the availability of an injection nor the fact that a product is a cloth answers which trial outcome matters to you.¹²³